Natalizumab (Tysabri) for relapsing multiple sclerosis

Med Lett Drugs Ther. 2005 Feb 14;47(1202):13-5.


Natalizumab (Tysabri), a selective adhesion molecule inhibitor, decreases the number of relapses and new brain lesions in patients with MS. Administered IV every 4 weeks, it is usually well tolerated, but anaphylaxis can occur and persistent neutralizing antibodies were reported in 6% of patients. No comparisons to other MS treatments and no data concerning its effect on progression of disability are currently available.

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Blood-Brain Barrier / drug effects
  • Cell Adhesion / drug effects
  • Humans
  • Injections, Intravenous
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab
  • Randomized Controlled Trials as Topic
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Natalizumab